Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of CD19 CAR-T cells in relapsed or refractory B-cell leukemia/lymphoma
ChiCTR1800018211Phase 2Recruiting
- Sponsor
- Luoyang Central Hospital
- Start
- Sep 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CART-19 cell in B cell acute lymphoblastic leukemia (B-ALL), mature B-cell lymphoma and B-cell malignancy, sponsored by Luoyang Central Hospital. Primary endpoints: Safety and Overall efficacy. Started Sep 2018; status: recruiting.
02
Drugs
CART-19 cell
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)mature B-cell lymphomaB-cell malignancy
Beyond the preview
Go deeper on ChiCTR1800018211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018211.